Mesa Laboratories posted fourth quarter fiscal 2026 results with 2.6% revenue growth and 87% operating income increase, while reducing debt by $14.7M. The life science tools company faces headwinds in its biopharmaceutical division due to export controls but expects return to positive growth in Q1 2027.